Lake Street Capital Cuts OS Therapies (NYSEAMERICAN:OSTX) Price Target to $17.00

OS Therapies (NYSEAMERICAN:OSTX) had its price target decreased by Lake Street Capital from $18.00 to $17.00 in a report published on Tuesday,Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

Several other brokerages have also issued reports on OSTX. Zacks Research upgraded OS Therapies from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. D. Boral Capital reissued a “buy” rating and set a $20.00 price target on shares of OS Therapies in a research note on Monday. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.33.

OS Therapies Stock Down 1.8%

NYSEAMERICAN OSTX opened at $1.62 on Tuesday. OS Therapies has a 52 week low of $1.12 and a 52 week high of $7.00. The firm has a market capitalization of $57.04 million, a price-to-earnings ratio of -1.98 and a beta of -4.10. The company has a fifty day moving average of $1.95 and a two-hundred day moving average of $1.89.

OS Therapies (NYSEAMERICAN:OSTX) last released its earnings results on Friday, November 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. Equities research analysts anticipate that OS Therapies will post -0.64 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CM Management LLC lifted its position in shares of OS Therapies by 172.6% in the 1st quarter. CM Management LLC now owns 300,000 shares of the company’s stock worth $462,000 after purchasing an additional 189,956 shares during the period. Susquehanna International Group LLP bought a new position in OS Therapies in the third quarter worth approximately $29,000. Ground Swell Capital LLC purchased a new stake in OS Therapies during the third quarter worth $40,000. Mercer Global Advisors Inc. ADV purchased a new stake in OS Therapies during the third quarter worth $40,000. Finally, Millennium Management LLC bought a new stake in OS Therapies during the 3rd quarter valued at $183,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.